Dozens of Clinics Market Risky Cell Therapies to Treat Eye Disorders

April 4, 2019

(Reuters) – Scores of clinics across the United States directly advertise expensive – but unproven – cell therapy procedures to patients with serious eye diseases, often with devastating results, a new study warns. Although there are no approved stem cell therapies to treat eye conditions in the U.S., when the authors of the study conducted a systematic internet search they found 40 companies with 76 clinics that advertised the procedures.

Recommended Reading